Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Stocks in this Quantisnow insightHealth Care
Historical context for JAZZ
Across the 29 sessions after earlier JAZZ headlines, the stock closed higher 21 times and lower 8 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JAZZ | SPY |
|---|---|---|---|
| Jun 9, 2026 | Truist resumed coverage on Jazz Pharma with a new price target | -1.2% | -0.3% |
| Jun 4, 2026 | Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia | +4.0% | +0.4% |
| May 28, 2026 | Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | -0.9% | +0.6% |
| May 22, 2026 | Bernstein initiated coverage on Jazz Pharma with a new price target | +0.2% | +0.4% |
| May 19, 2026 | Jazz Pharma upgraded by UBS with a new price target | +3.4% | -0.7% |
| May 13, 2026 | Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | +2.0% | +0.6% |
Quantisnow market dataNASDAQ
JAZZ
Jazz Pharmaceuticals plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2007
Get push alerts for JAZZ
Full JAZZ profile on Quantisnow Follow JAZZ and get a push notification the moment its next story breaks.